This product is a sulfonamide antibacterial drug. When used in combination with trimethoprim, it can double block the folic acid metabolism of bacteria and enhance the synergistic antibacterial effect. It has good antibacterial activity against a variety of bacteria, especially against Escherichia coli, Haemophilus influenzae, and Staphylococcus aureus. The antibacterial effect is significantly enhanced compared with single drugs.

This product is an antibacterial synergist that works by inhibiting dihydrofolate reductase. When used in combination with sulfamethoxazole, it can double block bacterial folic acid metabolism, enhance synergistic antibacterial effects, and reduce the emergence of drug-resistant strains.

This product has a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacilli. It has good antibacterial activity in vitro against the following bacteria: most bacteria of the Enterobacteriaceae family, including Citrobacter, cloacae, Enterobacter aerogenes, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. It often has antibacterial activity against multi-drug resistant bacteria. It has high antibacterial activity against penicillin-resistant Neisseria gonorrhoeae, enzyme-producing Haemophilus influenzae and Moraxella. It has antibacterial activity against most strains of Pseudomonas such as Pseudomonas aeruginosa. This product has antibacterial activity against methicillin-sensitive Staphylococcus, and only moderate antibacterial activity against Streptococcus pneumoniae, hemolytic Streptococcus and Enterococcus faecalis. It also has good effects on Chlamydia trachomatis, Mycoplasma, Legionella, and antibacterial activity against Mycobacterium tuberculosis and atypical mycobacteria. Poor antibacterial activity against anaerobic bacteria. Ciprofloxacin is a bactericide that acts on the A subunit of bacterial DNA gyrase, inhibiting DNA synthesis and replication, leading to bacterial death.

It can cause blood vessels to contract, reduce capillary permeability, enhance platelet aggregation and adhesion, promote platelets to release coagulation active substances, shorten coagulation time, and achieve hemostatic effect.

This product cannot be taken at the same time as enteric-coated tablets. If used at the same time with other drugs, drug interactions may occur. Please consult your doctor or pharmacist for details.

This product cannot be taken at the same time as enteric-coated tablets. If used at the same time with other drugs, drug interactions may occur. Please consult your doctor or pharmacist for details.

This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.